Abstract
At least since March 2020, the multiorgan disease COVID-19 has a firm grip on the world. Although most of the cases are mild, patients from risk populations could develop a cytokine storm, which is characterized by a systemic inflammatory response leading to acute respiratory distress syndrome and organ failure. The present paper will introduce the small molecule MP1032, describe its mode of action, and give rationale why it is a promising option for prevention/treatment of SARS-CoV-2-induced cytokine storm. MP1032 is a phase-pure anhydrous polymorph of 5-amino-2,3-dihydro-1,4-pthalazinedione sodium salt that exhibits good stability and bioavailability. The physiological action of MP1032 is based on a multi-target mechanism including localized, self-limiting antioxidant activities that were demonstrated in a model of lipopolysaccharide (LPS)-induced joint inflammation. Furthermore, immune-regulatory and PARP-1 modulating properties, coupled with antiviral effects against SARS-CoV-2 were shown in various cell models. Efficacy has been preclinically elucidated in LPS-induced endotoxemia, a model with excessively activated immune responses that shares many similarities to COVID-19. So far, during oral clinical development with three-months daily administrations, no serious adverse drug reactions occurred highlighting the outstanding safety profile of MP1032.
Competing Interest Statement
S.S., A.K., P.S., B.L., M.N., J.vW. are employees of MetrioPharm Deutschland GmbH F.N., K.M., P.F., E.vW., Y.Y., P.R., C.S. U.S. have nothing to disclose W.B. is employer, co-founder, and CEO of MetrioPharm AG The funders sponsored all the research but had no impact on the study results.
Clinical Trial
EudratCT-No: 2017-003484-36
Funding Statement
This research did not receive any specific grant from funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The clinical trial protocol was approved by the ethics committee of the State Chamber of Medicine in Rheinland-Pfalz (leading ethics committee in Germany; Internal file reference: 837.451.17 (11285)) and the ethics committee of the Country Medical Chamber in Rzeszow (leading ethics committee in Poland; Resolution No. 97/B/2017). The multi-center study was further approved by the German Federal Institute for Drugs and Medical Devices (BfArM,) Bonn (registration number 61-3910-4042376) and by the Polish President of The Office for Registration of Medical Products, Medical Devices and Biocidal Products, Warsaw (No. UR/DBL/D/044/2018).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author (SS).
10. Abbreviations
- 4-ANI
- 4-amino-1,8-naphthalimide
- ACE2
- Angiotensin-converting enzyme 2
- ARDS
- Acute respiratory distress syndrome
- COVID-19
- Corona virus disease 2019
- CD4
- Cluster of differentiation 4
- Dex
- Dexamethasone
- DMEM
- Dulbecco’s Modified Eagle’s Medium
- ELISA
- Enzyme-linked Immunosorbent Assay
- EtOH
- Ethanol
- FCS
- Fetal calf serum
- IL
- Interleukin
- LPS
- Lipopolysaccharide
- PARP-1
- Poly (ADP-ribose) polymerase 1
- PASI
- Psoriasis Area and Severity Index
- PBMC
- Peripheral blood mononuclear cells
- PBS
- Phosphate buffered saline
- PM
- Peritoneal macrophages
- PMA
- Phorbol 12-myristate 13-acetate
- RFU
- Relative fluorescence units
- ROS
- Reactive oxygen species
- SAE
- Serious adverse event
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus type 2
- SDS-PAGE
- Sodium dodecyl sulfate polyacrylamide gel electrophoresis SEM Standard error of the mean
- TEAE
- Treatment-emergent adverse event
- TNFα
- Tumor necrosis factor-alpha
- UPE
- Ultra-weak photon emission
- WST-1
- Water-soluble tetrazolium salt 1 assay
